Deepening our Commitment to Patients Suffering from Chemotherapy Induced Peripheral Neuropathy September 29th, 2025 NASDAQ: DWTX Agenda for Today Great Progress on Ongoing Halneuron® Phase 2b Chemotherapy Induced Pain Study Exciting New SP16 Cancer Related Pain Global License Overview Q&A NASDAQ: DWTX 2 Nav1.7 Research Pipeline Targeting Chronic and Acute Pain, Includes FDA Fast Track Designation for Treating CINP Target Indication Candidate/Target Preclinical Phase 1 Phase 2 Phase 3 Chemotherapy- Induced N ...